90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...
Fifteen healthcare organizations, including Loma Linda University Medical Center, have been selected to participate in a national study intended to enhance patient safety and quality of care in health ...
NEW YORK, March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that ...
NEW ORLEANS ― An interdisciplinary pilot program effectively deals with behavioral disturbances arising from delirium, dementia, or other mental illnesses in hospitalized older adults ― while keeping ...
At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients ...
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics ...
Using quadruplet regimens with anti-CD38 monoclonal antibodies, such as daratumumab (Darzalex) or isatuximab (Sarclisa), has significantly advanced frontline therapy for both transplant-eligible and ...
TURKU, FI / ACCESS Newswire / August 18, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel ...
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy "These data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results